platoseedplatoseed
AI platform accelerating therapies for rare & inflammatory diseases.
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
GEn1E Lifesciences is a clinical-stage company developing first-in-class, precision therapies for inflammatory rare diseases, leveraging an AI-driven platform to accelerate drug discovery and development. Their focus includes p38α/MK2 and ERK pathway modulators with a Pipeline in Phase 2. They emphasize a GRID AI platform and novel allosteric binding approaches to create selective dual signal modifiers.
GEn1E Lifesciences uses an AI-driven GRID platform that combines a rich data repository (public and proprietary) with machine learning models spanning drug discovery to clinical trials. The platform identifies new allosteric binding pockets beyond traditional ATP-binding sites, enabling selective dual signal modifiers (targeting kinases like p38α, MK2, ERK) with a differentiated mechanism of action. They generate 1st-in-class compounds, maintain assets in various phases (including a Phase 2 asset, GEn-1124, for ARDS), and pursue multiple preclinical programs via their integrated AI/biotech workflow.
Who it’s for: Biotech/pharma companies and research organizations aiming to develop precision therapies for inflammatory rare diseases, especially those seeking AI-assisted drug discovery and allosteric kinase inhibitors.
publications and media presence; corporate leadership appointments; Phase 2 study; multiple programs in preclinical/phase 2; seed funding mentioned
Formerly “Inc” · why startups rename →
Curative genetic medicines for kidney diseases
Arpeggio Bio develops drugs targeting transcription factors using AI…
